Pharmafile Logo

White paper: Are we prepared for the influx of CAR-Ts?

March 1, 2022 | Market Access, oncology 

Download this white paper, in which we look at how market access and hospital processes will need to transform to accommodate the the influx of CAR-T therapies

With CAR-Ts continuing to take centre stage as a paradigm shift in the treatment of cancer, Tania Rodrigues investigates how market access and hospital processes will need to transform to accommodate the influx of these innovative therapies.

Download the white paper here: https://bit.ly/36T8d5j

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Atopic Dermatitis — Going Beyond the Pill

Published in Pharma Exec April 2018 by Mariel Metcalfe

ESOMAR Asia Pacific 2018

13-15 May, Bangkok

Intellus Worldwide Summit 2018

Visit us on stand number 413

How buyer insights supported the development of an effective market strategy

Our client was developing a new product for HIV and needed to understand buyer willingness to pay in the emerging markets of South Africa, Kenya, and India. They needed to...

Conducting market research for scientific publication guide

Conducting and using market research for publication can be valuable for shaping opinions in healthcare. The findings can be used to influence existing perceptions, change current practices and behaviour in...

Therapy Watch appoints new Associate Director

Research Partnership has appointed Mark Hollis to join the Therapy Watch team as Associate Director. Mark has 8 years’ experience in syndicated healthcare, and previously worked in the Market Prognosis team at IQVIA...

Sabera Hyderally appointed Head of MedTech North America

Research Partnership is delighted to welcome Sabera Hyderally who has joined the company’s US headquarters in Philadelphia.

Full speed ahead: Unlock the full potential of your brand tracking

Wednesday 2nd May 2018 10:30 EST / 15:30 GMT / 16:30 CEST

How scenario testing helped assess demand for a brand launch in the fragmented NSCLC market

Our client was developing a new drug aimed at first line NSCLC patients. Ahead of its launch they wanted to assess likely uptake in an already fragmented market space led...